R Squared Ltd Invests $39,000 in Artivion, Inc. (NYSE:AORT)

R Squared Ltd bought a new position in Artivion, Inc. (NYSE:AORT) in the 4th quarter, Holdings Channel.com reports. The firm bought 1,370 shares of the company’s stock, valued at approximately $39,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. FMR LLC boosted its position in shares of Artivion by 28.0% in the third quarter. FMR LLC now owns 115,184 shares of the company’s stock worth $3,066,000 after buying an additional 25,176 shares during the period. Barclays PLC boosted its position in shares of Artivion by 346.3% in the third quarter. Barclays PLC now owns 70,877 shares of the company’s stock worth $1,888,000 after buying an additional 54,996 shares during the period. Lord Abbett & CO. LLC purchased a new stake in shares of Artivion in the third quarter worth about $5,798,000. JPMorgan Chase & Co. lifted its stake in shares of Artivion by 394.9% in the third quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock worth $2,606,000 after acquiring an additional 78,120 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Artivion by 58.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock worth $9,074,000 after acquiring an additional 125,668 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Analyst Upgrades and Downgrades

AORT has been the topic of several recent analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a research note on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and set a $34.00 price objective on shares of Artivion in a research note on Tuesday, January 28th. Finally, Oppenheimer upped their price objective on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Artivion has an average rating of “Buy” and an average target price of $31.80.

Artivion Stock Down 1.3 %

Shares of Artivion stock opened at $30.97 on Monday. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The business’s 50 day simple moving average is $29.52 and its 200-day simple moving average is $27.46. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -1,548.60 and a beta of 1.74. Artivion, Inc. has a twelve month low of $16.48 and a twelve month high of $32.33.

Insider Transactions at Artivion

In other Artivion news, SVP Jean F. Holloway sold 8,070 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total transaction of $243,068.40. Following the completion of the transaction, the senior vice president now directly owns 153,862 shares of the company’s stock, valued at approximately $4,634,323.44. This trade represents a 4.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Amy Horton sold 4,329 shares of the stock in a transaction on Friday, December 6th. The shares were sold at an average price of $29.66, for a total value of $128,398.14. Following the transaction, the chief accounting officer now directly owns 135,660 shares of the company’s stock, valued at approximately $4,023,675.60. The trade was a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 20,017 shares of company stock worth $600,007. 8.10% of the stock is currently owned by company insiders.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.